Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings (ATEC) reported Q2 revenue of $214M (+15% Y/Y) and surgical revenue of $196M (+17% Y/Y), alongside adjusted EBITDA of $36M (+53% Y/Y) with gross margin expanding 260 bps to 72.5%. The company generated $34M operating cash flow and $1M free cash flow (4th straight quarter positive), reaffirming full-year revenue guidance of ~$882M (~15% growth) while raising full-year adjusted EBITDA guidance to ~$140M (from ~$134M). Alphatec also consolidated legacy debt into a single JPMorgan/TD Cowen credit facility maturing in 2031, targeting >$6M annual interest expense savings, and reaffirmed full-year free cash flow of at least $20M.

Analysis

The important read-through is not just growth, but mix of growth becoming more durable: surgeon adds are leading case volume, and case volume is starting to translate into gross margin expansion and cash generation. That combination typically earns a higher multiple in med-tech because it de-risks the old “growth-at-any-cost” narrative and shifts the debate toward operating leverage. The market should also recognize that the EOS / informatics layer is a second-order wedge: it is less about selling hardware and more about owning the planning workflow, which can quietly raise switching costs and increase share of wallet over 6-18 months.

The main near-term loser is the entrenched spine-implant set: MDT and other large incumbents face a more competitive surgeon acquisition environment, especially with younger surgeons entering through the workflow/data doorway rather than legacy implant relationships. If EOS Insight truly lifts per-account utilization, the long-run effect is a redistribution of procedure economics toward ATEC at the expense of lower-frequency vendors whose share depends on one-off product sales rather than platform pull-through. That said, the biologics attach issue is the one place where the story can leak: if management needs to keep leaning on volume to offset weak attachment, the revenue-per-case comp will keep pressuring estimates and could cap multiple expansion.

Catalyst path: over the next 1-3 months, the stock should trade on whether Q3 shows the promised sequential stabilization in revenue per case and whether EOS placement/activation converts into measurable implant pull-through. Over 6-12 months, the real catalyst is whether EOS Insight penetrates beyond the current minority of the installed base and whether the company proves it can monetize deformity and pediatrics without sacrificing cash. Contrarian view: this may be less overhyped than it looks—consensus still seems to underweight the data moat—but the stock is vulnerable if the market decides the install base is growing faster than monetization. The clean falsifier is a Q3 miss on case growth or another quarter where biologics remain flat-to-down and gross margin stalls.

Key Decisions for Investors

• Buy ATEC on any post-earnings weakness over the next 1-2 weeks; thesis is 1-3 month re-rating as margin expansion and positive FCF become harder to dismiss. Falsify if Q3 surgical growth drops below high-teens or revenue per case worsens again.
• Pair trade: long ATEC / short MDT for 6-12 months. Rationale: ATEC has a faster surgeon-adoption and workflow-monetization curve, while MDT is more exposed to slower-share, mature implant economics. Cover the short if MDT spine commentary reaccelerates or ATEC biologics improve materially.
• Add ATEC only if EOS Insight penetration moves from 15-20% toward low-30s by year-end; otherwise treat EOS as optionality, not core value. This is the key watch item for the next 2 quarters.
• If you want downside protection, use a tight risk-control stop rather than options: exit/reduce if management reaffirms revenue but cuts EBITDA or FCF guidance, which would signal the set/inventory investments are not converting into pull-through.
• For event-driven traders, buy the stock into confirmation of Q3 margin expansion rather than on install-count hype. The cleaner catalyst is proof that gross margin stays in the low-70s while biologics attach stabilizes; that is what expands the multiple.